EUVIMEDEUVIMED entdecken
Crossref

Paclitaxel‐carboplatin plus bevacizumab therapy for advanced neuroendocrine carcinoma of the uterine cervix: A retrospective case series

Saki Kotaka iD, Eiji Kondo iD, Yosuke Kawai, Kota Okamoto, Yasuyuki Kishigami, Takaharu Yamawaki, Kenji Nagao, Hirata Toru, Shiro Suzuki iD

Journal of Obstetrics and Gynaecology Research · 2023

DOI: 10.1111/jog.15783 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Obstetrics and Gynaecology Research, 2023. Verfasst von Saki Kotaka und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecologic Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Carcinoma, Neuroendocrine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

There is no conclusive data on the prognosis of patients who receive paclitaxel‐carboplatin (TC) plus bevacizumab therapy for advanced neuroendocrine carcinoma (NEC) of the uterine cervix, a rare histological subtype of cervical cancer. Thus, the aim of this study was to determine the efficacy of TC chemotherapy plus bevacizumab and bevacizumab single maintenance therapy for advanced NEC of the cervix.

Methods

This was a retrospective review of patients who received TC plus bevacizumab therapy for metastatic, recurrent, or persistent NEC of the cervix at seven institutions between 2015 and 2020. Relevant data were extracted from the patients' medical records and analyzed.

Results

Seven patients, including six with small‐cell NEC and one with large‐cell NEC, were included for analysis. Three patients received bevacizumab single maintenance therapy following TC plus bevacizumab therapy, whereas four patients did not receive bevacizumab single maintenance therapy. The median overall survival and progression‐free survival of the patients who received bevacizumab single maintenance therapy were longer than those of the patients who did not receive the therapy (34 months vs. 10.5 months and 19 months vs. 5 months, respectively). However, the patients who received bevacizumab single maintenance therapy had received cisplatin‐based chemotherapy previously.

Conclusions

On the premise that cisplatin‐based chemotherapy is administered as the first‐line treatment for advanced NEC of the cervix, bevacizumab single maintenance therapy following TC plus bevacizumab may be considered the second‐ or third‐line treatment. However, the risk of adverse events, such as intestinal perforation, should be discussed with patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsCarcinoma, NeuroendocrineFemaleHumansBevacizumabCarboplatinPaclitaxelCisplatinRetrospective StudiesCervix UteriAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

bevacizumabchemotherapyneuroendocrine carcinomasmall-cell carcinomauterine cervical cancer

Substanzen

BevacizumabCarboplatinPaclitaxelCisplatin

Autor:innen und Institutionen

  • Department of Gynecologic Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan.
  • Department of Obstetrics and Gynecology, Mie University School of Medicine, Tsu, Mie, Japan.
  • Department of Obstetrics and Gynecology, Kuwana City Medical Center, Kuwana, Mie, Japan.
  • Department of Obstetrics and Gynecology, Toyohashi Municipal Hospital, Toyohashi, Aichi, Japan.
  • Department of Obstetrics and Gynecology, Toyota Memorial Hospital, Toyota, Aichi, Japan.
  • Department of Obstetrics and Gynecology, Ise Red Cross Hospital, Ise, Mie, Japan.

ORCID-Profile: Saki Kotaka, Eiji Kondo, Shiro Suzuki

Zitieren

APA

Kotaka, S., Kondo, E., Kawai, Y., Okamoto, K., Kishigami, Y., Yamawaki, T., Nagao, K., Toru, H., & Suzuki, S. (2023). Paclitaxel‐carboplatin plus bevacizumab therapy for advanced neuroendocrine carcinoma of the uterine cervix: A retrospective case series. Journal of Obstetrics and Gynaecology Research. https://doi.org/10.1111/jog.15783

Vancouver

Kotaka S, Kondo E, Kawai Y, Okamoto K, Kishigami Y, Yamawaki T, et al. Paclitaxel‐carboplatin plus bevacizumab therapy for advanced neuroendocrine carcinoma of the uterine cervix: A retrospective case series. Journal of Obstetrics and Gynaecology Research. 2023. doi:10.1111/jog.15783

BibTeX
@article{Kotaka2023,
  author = {Kotaka, Saki and Kondo, Eiji and Kawai, Yosuke and Okamoto, Kota and Kishigami, Yasuyuki and Yamawaki, Takaharu and Nagao, Kenji and Toru, Hirata and Suzuki, Shiro},
  title = {Paclitaxel‐carboplatin plus bevacizumab therapy for advanced neuroendocrine carcinoma of the uterine cervix: A retrospective case series},
  journal = {Journal of Obstetrics and Gynaecology Research},
  year = {2023},
  doi = {10.1111/jog.15783}
}
Kostenlos starten →